Unpredicted human safety events in clinical trials for new drugs are costly in terms of human health and money. The drug discovery industry attempts to minimize those events with diligent preclinical ...
Health Canada gratefully acknowledges the contribution of the following people in reviewing chapters. Health Canada recognizes the particular efforts of Jean-Christophe Blachère PhD and Pierre ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback